Filing Details

Accession Number:
0001638599-16-001038
Form Type:
4
Zero Holdings:
No
Publication Time:
2016-06-06 17:34:50
Reporting Period:
2016-06-03
Filing Date:
2016-06-06
Accepted Time:
2016-06-06 17:34:50
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1410098 Cormedix Inc. CRMD Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1535481 Matthew Duffy C/O Cormedix Inc.
745 Route 202-206, Suite 303
Bridgewater NJ 08807
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock, $0.001 Par Value Per Share Disposition 2016-06-03 46,106 $2.73 28,571 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Direct
Reported Derivative Holdings
Sec. Name Sec. Type Price Date Expiration Date Amount Remaning Holdings Nature of Ownership
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $2.02 2024-01-09 150,000 150,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $2.02 2024-01-09 30,000 30,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $0.90 2023-03-20 100,000 100,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $0.68 2022-12-05 125,000 125,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $0.29 2022-01-06 5,000 5,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $0.28 2021-11-21 15,000 15,000 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $5.62 2025-03-01 50,000 50,000 Direct
Common Stock, $0.001 Par Value Per Share Phantom Stock $0.00 594 594 Direct
Common Stock, $0.001 Par Value Per Share Stock Option (right to buy) $1.91 2026-02-21 75,000 75,000 Direct
Common Stock, $0.001 Par Value Per Share Phantom Stock $0.00 1,653 1,653 Direct
Common Stock, $0.001 Par Value Per Share Phantom Stock $0.00 1,153 1,153 Direct
Expiration Date Amount Remaning Holdings Nature of Ownership
2024-01-09 150,000 150,000 Direct
2024-01-09 30,000 30,000 Direct
2023-03-20 100,000 100,000 Direct
2022-12-05 125,000 125,000 Direct
2022-01-06 5,000 5,000 Direct
2021-11-21 15,000 15,000 Direct
2025-03-01 50,000 50,000 Direct
594 594 Direct
2026-02-21 75,000 75,000 Direct
1,653 1,653 Direct
1,153 1,153 Direct
Footnotes
  1. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.67 to $2.77, inclusive.
  2. These options vested 100% on January 10, 2014.
  3. These options vest in full on the first anniversary of the date of grant.
  4. These options vest quarterly over two years.
  5. These options vest as follows: (a) fifty percent (50%) on the date of issuance of the CE Mark certification for Neutrolin in Europe, which occurred on July 5, 2013, and (b) fifty percent (50%) on December 31, 2013.
  6. The options vest ratably, one-third of which will vest on each of the grant date, the first anniversary and the second anniversary thereof.
  7. Each share of phantom stock is the economic equivalent of one share of common stock. The shares of phantom stock become payable in common stock on the tenth business day of January of the year following the reporting person's termination of service as a directo